ECBF has supplied an extension to Aphea.Bio’s series B round, which already included Gemma Frisius Fund, Qbic, Vives and V-Bio Ventures.

Aphea.Bio, a Belgium-based agriculture technology provider spun out of multiple institutions, increased its series B round to €18m ($21.8m) today following an extension supplied by the European Circular Bioeconomy Fund.
The company secured an initial $16.8m from investors including KU Leuven’s Gemma Frisius Fund, multi-university venture fund Qbic II, VIB-affiliated fund V-Bio Ventures and Vives Fund, an investment vehicle for Université catholique de Louvain.
The first close was led by Astanor Ventures and also featured agriculture and environmental…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in